MedTrace Logo

A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients

NCT01468493 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2017-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

Conditions

  • FSGS

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Wei Shi, MD,PhD · Nephrology Dept.,Guangdong General Hospital

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468493 on ClinicalTrials.gov